Chasing Lilly, Concert eyes 2023 filing for its JAK drug for...

Concert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia areata (AA), a common cause of hair loss, and says it hopes to report results

PureTech unit Follica cues up phase 3 programme for male hai...

PureTech has said one of the companies it has founded – Follica – is preparing to start registration trials for its drug-device therapy for treating male pattern baldness in th

FDA gives Lilly’s Olumiant breakthrough status for hair loss

Allergan bolsters aesthetics pipeline with Exicure hair loss...